Results 201 to 210 of about 230,682 (392)

IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis

open access: yesCardiovascular Research, 2018
C. Chou   +12 more
semanticscholar   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata   +19 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt   +16 more
wiley   +1 more source

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...
Toru Kondo   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy